Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 4:08 PM
Ignite Modification Date: 2025-12-24 @ 4:08 PM
NCT ID: NCT01533766
Eligibility Criteria: Inclusion Criteria: * Patients aged 20 and older * Patients are expected to require PN for more than 5 days * Patients who voluntarily signed the consent form Exclusion Criteria: * Patients are expected difficult to survive more than 5 days * Pregnant or breast-feeding women * BMI \> 30 kg/m2 * Patients with severe blood coagulation disorders * Patients with congenital amino acid metabolism disorders * Patients with acute shock * Patients with uncontrollable diabetes mellitus * Patients with hemophage syndrome * Patients with hypopotassemia (K \< 3.0mEq/L) * Patients having the history of myocardial infarction * Patients reported the following laboratory value * fasting TG \> 250mg/dl, TC \> 300mg/dl * ALT/AST ≥ 2×ULN, Bilirubin ≥ 3mg/dl (Exception : patients with periampullary carcinoma including biliary tract or pancreas) * Creatinine ≥ 1.5mg/dl * Ca \> 11.2mg/dl, Na ≥ 145mEq/L, Mg ≥ 2.1mEq/L, K ≥ 5.5mEq/L * Patients having hypersensitivity to any peanut-, fish-, soy-, egg protein, or investigational drug * Patients having the history of drug or alcohol abuse * General contraindications to infusion therapy: acute pulmonary oedema, hyperhydration, cardiac decompensation * Patients are in unstable conditions * Patients with difficult peripheral intravenous * Patients with parenteral nutrition within 7 days prior to start of the trial * Participation in another clinical study with an investigational drug or an investigational medical device within 28 days prior to start of study * Patients judged to be unsuitable for this trial by investigators
Healthy Volunteers: False
Sex: ALL
Minimum Age: 20 Years
Study: NCT01533766
Study Brief:
Protocol Section: NCT01533766